W. Rathmell
Last active: 4/27/2021

  1. Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. Rini B, Abel EJ, Albiges L, Bex A, Brugarolas J, Bukowski RM, Coleman JA, Drake CG, Figlin RA, Futreal A, Hammers H, Powles T, Rathmell WK, Ricketts CJ, Turajlic S, Wood CG, Leibovich BC (2021) Clin Genitourin Cancer 19(2): 167-175
    › Primary publication · 33358149 (PubMed)
  2. Pushing the boundaries with collision collaboration: the marriage of ideas. Rathmell JC, Rathmell WK (2021) J Clin Invest 131(2)
    › Primary publication · 33463534 (PubMed) · PMC7810468 (PubMed Central)
  3. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, Mayer TM, Riedlinger GM, Vincent BG, Davis NB, Haake SM, Rathmell JC, Jonasch E, Rini BI, Rathmell WK, Beckermann KE (2021) Cancers (Basel) 13(6)
    › Primary publication · 33806963 (PubMed) · PMC8004696 (PubMed Central)
  4. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Jonasch E, Walker CL, Rathmell WK (2021) Nat Rev Nephrol 17(4): 245-261
    › Primary publication · 33144689 (PubMed) · PMC8172121 (PubMed Central)
  5. Cell-programmed nutrient partitioning in the tumour microenvironment. Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, Sugiura A, Cohen AS, Ali A, Do BT, Muir A, Lewis CA, Hongo RA, Young KL, Brown RE, Todd VM, Huffstater T, Abraham A, O'Neil RT, Wilson MH, Xin F, Tantawy MN, Merryman WD, Johnson RW, Williams CS, Mason EF, Mason FM, Beckermann KE, Vander Heiden MG, Manning HC, Rathmell JC, Rathmell WK (2021) Nature 593(7858): 282-288
    › Primary publication · 33828302 (PubMed) · PMC8122068 (PubMed Central)
  6. A cytoskeletal function for PBRM1 reading methylated microtubules. Karki M, Jangid RK, Anish R, Seervai RNH, Bertocchio JP, Hotta T, Msaouel P, Jung SY, Grimm SL, Coarfa C, Weissman BE, Ohi R, Verhey KJ, Hodges HC, Burggren W, Dere R, Park IY, Prasad BVV, Rathmell WK, Walker CL, Tripathi DN (2021) Sci Adv 7(14)
    › Primary publication · 33811077 (PubMed)
  7. The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase. Seervai RNH, Jangid RK, Karki M, Tripathi DN, Jung SY, Kearns SE, Verhey KJ, Cianfrocco MA, Millis BA, Tyska MJ, Mason FM, Rathmell WK, Park IY, Dere R, Walker CL (2020) Sci Adv 6(40)
    › Primary publication · 33008892 (PubMed) · PMC7852384 (PubMed Central)
  8. The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. Moslehi J, Rathmell WK (2020) J Clin Invest 130(1): 4-6
    › Primary publication · 31763994 (PubMed) · PMC6934228 (PubMed Central)
  9. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S, MC3 Working Group, PCAWG novel somatic mutation calling methods working group, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L, PCAWG Consortium (2020) Nat Commun 11(1): 4748
    › Primary publication · 32958763 (PubMed) · PMC7505971 (PubMed Central)
  10. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. Wood CG, Ferguson JE, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, Rathmell WK (2020) JCI Insight 5(22)
    › Primary publication · 33208553 (PubMed) · PMC7710285 (PubMed Central)